Abpro (ABP) versus Its Competitors Critical Survey

Abpro (NASDAQ:ABP) is one of 617 public companies in the “MED – BIOMED/GENE” industry, but how does it compare to its peers? We will compare Abpro to similar companies based on the strength of its analyst recommendations, profitability, dividends, risk, valuation, institutional ownership and earnings.

Insider & Institutional Ownership

23.3% of Abpro shares are held by institutional investors. Comparatively, 51.2% of shares of all “MED – BIOMED/GENE” companies are held by institutional investors. 13.7% of Abpro shares are held by company insiders. Comparatively, 13.6% of shares of all “MED – BIOMED/GENE” companies are held by company insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a stock will outperform the market over the long term.

Valuation & Earnings

This table compares Abpro and its peers top-line revenue, earnings per share (EPS) and valuation.

	Gross Revenue	Net Income	Price/Earnings Ratio
Abpro	$180,000.00	-$7.23 million	-1.64
Abpro Competitors	$966.98 million	-$45.82 million	12.92

Abpro’s peers have higher revenue, but lower earnings than Abpro. Abpro is trading at a lower price-to-earnings ratio than its peers, indicating that it is currently more affordable than other companies in its industry.

Volatility & Risk

Abpro has a beta of 0.01, meaning that its stock price is 99% less volatile than the S&P 500. Comparatively, Abpro’s peers have a beta of 0.97, meaning that their average stock price is 3% less volatile than the S&P 500.

Profitability

This table compares Abpro and its peers’ net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
Abpro	N/A	N/A	-344.76%
Abpro Competitors	-1,425.99%	-589.65%	-28.81%

Analyst Ratings

This is a breakdown of current recommendations for Abpro and its peers, as provided by MarketBeat.com.

	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Abpro	1	1	0	0	1.50
Abpro Competitors	5782	12208	37668	1170	2.60

Abpro presently has a consensus target price of $120.00, suggesting a potential upside of 1,631.60%. As a group, “MED – BIOMED/GENE” companies have a potential upside of 50.95%. Given Abpro’s higher probable upside, equities research analysts clearly believe Abpro is more favorable than its peers.

Summary

Abpro peers beat Abpro on 8 of the 13 factors compared.

About Abpro

Abpro Holdings Inc. is a biotechnology company. The company’s mission is to improve the lives of mankind facing severe and life-threatening diseases with next-generation antibody therapies. Abpro Holdings Inc., formerly known as Atlantic Coastal Acquisition Corp. II, is based in WOBURN, Mass.